NasdaqCM - Nasdaq Real Time Price USD

TG Therapeutics, Inc. (TGTX)

34.17

-0.68

(-1.95%)

As of 2:54:25 PM EDT. Market Open.

TG Therapeutics First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

TG Therapeutics ( NASDAQ:TGTX ) First Quarter 2025 Results Key Financial Results Revenue: US$120.9m (up 90% from 1Q...

Simply Wall St. 2 days ago

TGTX
-1.95%
TG Therapeutics Inc (TGTX) Q1 2025 Earnings Call Highlights: Strong BRIUMVI Sales and Increased ...

TG Therapeutics Inc (TGTX) reports impressive growth in BRIUMVI sales and raises its full-year revenue outlook, despite facing competitive market challenges.

GuruFocus.com 2 days ago

TGTX
-1.95%
Q1 2025 TG Therapeutics Inc Earnings Call

Q1 2025 TG Therapeutics Inc Earnings Call

Thomson Reuters StreetEvents 2 days ago

TGTX
-1.95%
Why TG Therapeutics Stock Was Tumbling Today

A huge miss on the bottom line drove investors away from the shares. The company, best known for its multiple sclerosis (MS) drug Briumvi, posted its first-quarter results that morning, and investors expressed their displeasure by trading out of the stock aggressively. TG's revenue is comprised almost entirely of Briumvi sales, so when those sales improve so does the company's revenue line.

Motley Fool 2 days ago

TGTX
-1.95%
TG Therapeutics (TGTX) Lags Q1 Earnings Estimates

TG Therapeutics (TGTX) delivered earnings and revenue surprises of -83.33% and 1.99%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks 3 days ago

TGTX
-1.95%
TG Therapeutics: Q1 Earnings Snapshot

MORRISVILLE, N.Y. (AP) — TG Therapeutics Inc. TGTX) on Monday reported first-quarter earnings of $5.1 million. The Morrisville, New York-based company said it had net income of 3 cents per share.

Associated Press Finance 3 days ago

TGTX
-1.95%
TG Therapeutics Reports First Quarter 2025 Financial Results and Raises BRIUMVI Full Year Revenue Guidance

First quarter 2025 BRIUMVI U.S. net revenue of $119.7 million Raises full year 2025 global net revenue target to approximately $575 million and raises full year BRIUMVI U.S. net revenue target to approximately $560 million Conference call to be held today, Monday, May 5, 2025, at 8:30 AM ET NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) (the Company or TG Therapeutics) today announced its financial results for the first quarter of 2025, along with recent company

GlobeNewswire 3 days ago

TGTX
-1.95%
TG Therapeutics (TGTX) to Report Q1 Results: Wall Street Expects Earnings Growth

TG Therapeutics (TGTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 8 days ago

TGTX
-1.95%
TG Therapeutics to Host Conference Call on First Quarter 2025 Financial Results and Business Update

Conference call to be held Monday, May 5, 2025, at 8:30 AM ETNEW YORK, April 30, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Monday, May 5, 2025, at 8:30 AM ET to discuss results for the first quarter of 2025 and provide a business outlook for the remainder of 2025. Michael S. Weiss, Chairman and Chief Executive Officer, will host the call. In order to participate in the conference call, please call 1-877-407-8029 (U.S.), 1-

GlobeNewswire 8 days ago

TGTX
-1.95%
TG Therapeutics (NasdaqCM:TGTX) Sees Profitable Turn With Strong Quarterly Earnings

TG Therapeutics (NasdaqCM:TGTX) experienced a notable price increase of 24% over the last quarter, which aligns with positive developments regarding its product, BRIUMVI, at a prestigious medical conference. The favorable reception and strong earnings results, transitioning from a loss to profitability, alongside clear corporate revenue guidance, likely bolstered investor confidence. Despite a generally volatile market, TG Therapeutics’ share buyback program and projection of substantial...

Simply Wall St. 10 days ago

TGTX
-1.95%
Exploring US High Growth Tech Stocks

Over the last 7 days, the United States market has experienced a 3.0% drop, although it has risen by 4.6% over the past year, with earnings anticipated to grow by 14% annually in the coming years. In this context of fluctuating yet optimistic growth prospects, identifying high-growth tech stocks requires careful consideration of their innovation potential and ability to capitalize on emerging trends within a dynamic market environment.

Simply Wall St. 21 days ago

LEGN

TGTX
-1.95%

NFLX
TG Therapeutics Shares Rise Almost 30% in 3 Months: Here's Why

Strong adoption of TGTX's sole marketed product, Briumvi, approved for treating relapsing forms of multiple sclerosis, is driving the top line.

Zacks 28 days ago

TGTX
-1.95%
TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting

NEW YORK, April 10, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), announced the presentation of data yesterday highlighting BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the American Academy of Neurology 2025 annual meeting. Links to each presentation are included below. Michael S. Weiss, Chief Executive Officer and Chairman of TG Therapeutics stated, "We are encouraged by the results from the ENHANCE trial presented yesterday, whic

GlobeNewswire 28 days ago

TGTX
-1.95%
TG Therapeutics Announces Two Publications Highlighting BRIUMVI in Medical Journals

NEW YORK, April 07, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the publication of two journal articles one describing the evolution of CD20 treatments for multiple sclerosis (MS) and the other detailing the experience of seven individuals with MS who switched to BRIUMVI® (ublituximab-xiiy) from a different anti-CD20 monoclonal antibody therapy due to efficacy or tolerability concerns. Details of the publications are provided below. Michael S. Weiss, the Company

GlobeNewswire last month

TGTX
-1.95%
IBD 50 Stock TG Therapeutics Rallies On A Setback For Chief Rival Roche

TG Therapeutics rallied Wednesday after Roche's rival multiple sclerosis treatment, Ocrevus, missed its mark in a study.

Investor's Business Daily last month

TGTX
-1.95%
Should We Be Cautious About TG Therapeutics, Inc.'s (NASDAQ:TGTX) ROE Of 11%?

While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...

Simply Wall St. last month

TGTX
-1.95%
These Insurance Stocks And Biotech Leader Hit New Highs As Stock Market Crumbles

Insurance stock Root soared to a new high on Friday. The IBD 50 holding has an ideal Composite and Relative Strength Rating.

Investor's Business Daily last month

KRMN

ROOT

TGTX
-1.95%
TG Therapeutics (TGTX): Among the Best Short Squeeze Stocks to Buy According to Analysts

We recently shared a list of 10 Best Short Squeeze Stocks To Buy According to Analysts. In this article, we will see how TG Therapeutics, Inc. (NASDAQ:TGTX) compares to the other top short squeeze stocks that have received a Buy rating from analysts. Stock market trading has an ever-changing environment. Short squeeze is among the […]

Insider Monkey last month

TGTX
-1.95%
Strength Seen in TG Therapeutics (TGTX): Can Its 10.2% Jump Turn into More Strength?

TG Therapeutics (TGTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Zacks last month

TGTX
-1.95%

CUE
Is TG Therapeutics, Inc. (TGTX) the Best Performing Growth Stock in 2025?

We recently published a list of 10 Best Performing Growth Stocks in 2025 In this article, we are going to take a look at where TG Therapeutics, Inc. (NASDAQ:TGTX) stands against other best performing growth stocks in 2025. Heavy AI investments and the tariffs uncertainty have been putting pressure on the technology and growth sector. […]

Insider Monkey last month

TGTX
-1.95%

Performance Overview

Return	TGTX	S&P 500 (^GSPC)
YTD	+13.39%	-3.04%
1-Year	+99.36%	+9.94%
3-Year	+382.06%	+38.31%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

TG Therapeutics, Inc. (TGTX)

TG Therapeutics First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

TG Therapeutics Inc (TGTX) Q1 2025 Earnings Call Highlights: Strong BRIUMVI Sales and Increased ...

Q1 2025 TG Therapeutics Inc Earnings Call

Why TG Therapeutics Stock Was Tumbling Today

TG Therapeutics (TGTX) Lags Q1 Earnings Estimates

TG Therapeutics: Q1 Earnings Snapshot

TG Therapeutics Reports First Quarter 2025 Financial Results and Raises BRIUMVI Full Year Revenue Guidance

TG Therapeutics (TGTX) to Report Q1 Results: Wall Street Expects Earnings Growth

TG Therapeutics to Host Conference Call on First Quarter 2025 Financial Results and Business Update

TG Therapeutics (NasdaqCM:TGTX) Sees Profitable Turn With Strong Quarterly Earnings

Exploring US High Growth Tech Stocks

TG Therapeutics Shares Rise Almost 30% in 3 Months: Here's Why

TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting

TG Therapeutics Announces Two Publications Highlighting BRIUMVI in Medical Journals

IBD 50 Stock TG Therapeutics Rallies On A Setback For Chief Rival Roche

Should We Be Cautious About TG Therapeutics, Inc.'s (NASDAQ:TGTX) ROE Of 11%?

These Insurance Stocks And Biotech Leader Hit New Highs As Stock Market Crumbles

TG Therapeutics (TGTX): Among the Best Short Squeeze Stocks to Buy According to Analysts

Strength Seen in TG Therapeutics (TGTX): Can Its 10.2% Jump Turn into More Strength?

Is TG Therapeutics, Inc. (TGTX) the Best Performing Growth Stock in 2025?

Performance Overview